





Team 7: CMT4J

Nithin Parsan, John Yang, Yunseo Jo, Alex Quach




Background on CMT4J

- CMT4J is an ultra-rare form of hereditary neuropathy (1/1,000,000).
- Caused by a mutation in the FIG4 gene:
 - Autosomal recessive inheritance, commonly I41T/null (60/100).
 - Mutation reduces binding affinity but can be rescued.
- Clinically presents itself with high variability, often misdiagnosed e.g. CIDP.
- AAV gene therapy recruiting for clinical trial.



Vacuolation => spongiform encephalopathy (Lenk 2011)

FIG4 Variants Are Difficult to Categorize



- Lack of data for non-classical genotypes, affects **clinical trial eligibility**.
- FIG4 disease severity varies significantly. Why?
- Broad Institute frequency analysis says there should be more 4J cases

Goal: Characterize FIG4 Variants Using *in silico* Methods and Case Studies To Compensate For Low Sample Sizes

Data

ClinVar, gnomAD variants of FIG4
AlphaMissense predictions for AA
mutation pathogenicity

Case Studies of 4J, ALS-11, YV,
etc.

Fig4 + Vac14 structure

Methods

Correlate Pathogenicity with *in silico* Binding Affinity Data

Easy-to-compute, general across
diseases, relevant for AAV trial


Score FIG4 Variants in Literature Across The Spectrum

Many Variants of Unknown
Significance (VUS), in-silico
scoring is cheap preliminary look.

Results


Binding complex visualization enriched with predicted pathogenicity

- Predicted binding pocket of Vac14 and FgHgg (0.97)
- Near binding interface
- Residues colored according to average predicted pathogenicity
- high pathogenicity at binding interface and active site



Results

ClinVar annotations for AlphaMissense predictions (as of all uncertain VUSs) mutations show high agreement of pathogenicity from VUSs residue 480 - 550



Discussion + Future Directions

Discussion

- Characterized 438 protein missense variants of FIG4 using AlphaMissense
- Binding complex structure enrichment with predicted pathogenicity is validated by clinically relevant mutations

Future Directions

- Use AI for protein optimization → novel AAV therapeutics with longer lasting + higher affinity FIG4
- Investigate sphingosine 1-phosphate as immunogenic biomarker. Fingolimod could be therapeutic as in MS.